Department of Urology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Urology, "Prof Dr. Ion Chiricuta" Oncology Institute, 400015 Cluj-Napoca, Romania.
Genes (Basel). 2024 May 4;15(5):584. doi: 10.3390/genes15050584.
MicroRNAs (miRNAs) are a class of small non-coding RNAs that may function as tumor suppressors or oncogenes. Alteration of their expression levels has been linked to a range of human malignancies, including cancer. The objective of this investigation is to assess the relative expression levels of certain miRNAs to distinguish between prostate cancer (PCa) from benign prostatic hyperplasia (BPH). Blood plasma was collected from 66 patients diagnosed with BPH and 58 patients with PCa. Real-time PCR technology was used to evaluate the relative expression among the two groups for miR-106a-5p and miR-148a-3p. The significant downregulation of both miRNAs in plasma from PCa versus BPH patients suggests their potential utility as diagnostic biomarkers for distinguishing between these conditions. The concurrent utilization of these two miRNAs slightly enhanced the sensitivity for discrimination among the two analyzed groups, as shown in ROC curve analysis. Further validation of these miRNAs in larger patient cohorts and across different stages of PCa may strengthen their candidacy as clinically relevant biomarkers for diagnosis and prognosis.
微小 RNA（miRNAs）是一类小的非编码 RNA，可能作为肿瘤抑制因子或癌基因发挥作用。它们的表达水平的改变与多种人类恶性肿瘤有关，包括癌症。本研究的目的是评估某些 miRNAs 的相对表达水平，以区分前列腺癌（PCa）和良性前列腺增生（BPH）。从 66 名诊断为 BPH 的患者和 58 名 PCa 患者中采集血浆。实时 PCR 技术用于评估两组间 miR-106a-5p 和 miR-148a-3p 的相对表达。与 BPH 患者相比，PCa 患者血浆中这两种 miRNA 的显著下调表明它们可能作为区分这些疾病的诊断生物标志物具有潜在的应用价值。ROC 曲线分析显示，这两种 miRNA 的联合使用略微提高了对两个分析组的区分灵敏度。在更大的患者队列和不同阶段的 PCa 中进一步验证这些 miRNA，可能会增强它们作为临床相关诊断和预后生物标志物的候选资格。
